ESMO 2026 has ended. This guide stays up as the record of who was there. Next: ESMO 2027, Sep 17–21, 2027 in Barcelona
Melanoma Institute Australia at ESMO 2026
Oct 23–27, 2026 Madrid, Spain ~37k attendees Website
Melanoma Institute Australia takes part in 6 sessions at ESMO 2026 in Madrid. Its sessions centre on melanoma biomarkers and immunotherapy. They examine immune-related liver injury and treatment resistance, and compare an individualized mRNA-based neoantigen therapy plus pembrolizumab with pembrolizumab alone after melanoma surgery.
| Organization | ESMO 2026 Attendance |
|---|---|
Melanoma Institute Australia Wollstonecraft, Australia | |
Nonprofit melanoma research and treatment centre in Sydney, Australia, affiliated with the University of Sydney. | Poster Fri Oct 23 13:00–15:00 Clinical and blood biomarkers associated with high-grade immune-related hepatitis (irHep) in immune checkpoint inhibitor (ICI)-treated melanoma Melanoma & skin cancersBiomarkers & precision oncology Poster Fri Oct 23 15:15–16:00 Poster Sat Oct 24 12:00–12:45 Talk Sat Oct 24 15:10–15:35 Lymph nodes under the knife Melanoma & skin cancers Abstract Sat Oct 24 16:30–16:42 LBA1 - INTerpath-001: Phase 3 study of the mRNA-based individualized neoantigen therapy (INT) intismeran autogene (intismeran) plus pembrolizumab (pembro) vs pembro alone for adjuvant treatment of resected stage IIB-IV melanoma (MEL) Lung & thoracic cancersMelanoma & skin cancersGenitourinary cancers Satellite Sun Oct 25 19:20–19:40 Neoadjuvant or Adjuvant Therapies for Stage II Melanoma Melanoma & skin cancers Satellite Sun Oct 25 19:40–20:00 Audience Q&A and Panel Discussion Melanoma & skin cancers |
Find decision makers at Melanoma Institute Australia
Tell us what you sell and we’ll find the people at Melanoma Institute Australia most likely to buy it.
- Who to contact
- Their contact info
- What to say
- Free, no sign-up
Not affiliated with or endorsed by the European Society for Medical Oncology. Submit a correction